Session 1 – A Fascinating Year of Biotech Innovation and Investment
Date: 24 July (Wednesday) 14:00 - 16:30 Venue: 3F, Bldg. A, CTBC Financial Park, Ballroom A
Merck Sharp & Dohme
Min has 15 years of pharmaceutical and biotech R&D and business development experience.
Min is currently Executive Director of the Asia Pacific Innovation Hub of MSD, responsible for R&D business development (in-licensing/M&A) in various therapeutic areas (Oncology, Immunology, Inflammation, Metabolic Disorders, Cardiovascular Diseases, Infectious Diseases and CNS) and enabling technology covering the Greater China area. Before MSD, she was the Head of External R&D and Licensing for Amgen Asia R&D Center, responsible for the center’s scientific outreach and alliance management of the external strategic partnerships. She was also in charge of Search & Evaluation for Amgen’s Global Business Development for the JPAC region. Min worked in different functions at Roche including Partnering, Alliance and Portfolio Management.
Min obtained her Ph.D. in computational biology and chemistry from New York University, conducted post-doctoral research at Pfizer La Jolla site and subsequently worked as principle scientist at GlaxoSmithKline in North Carolina. Min has an MBA from University of Manchester, UK